{"ModuleTitle": "Company Description", "CompanyName": "AcelRx Pharmaceuticals, Inc.", "Symbol": "ACRX", "Address": "351 GALVESTON DRIVE, REDWOOD CITY, California, 94063, United States of America", "Phone": "650-216-3500", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a specialty pharmaceutical company focused on the development and\r\ncommercialization of innovative therapies for use in medically supervised\r\nsettings.\r\n\r\n \r\n\r\nOur Portfolio\r\n\r\n \r\n\r\nThe following table summarizes our portfolio.\r\n\r\n \r\n\r\nUnited States                                                                               \r\n                                                                                            \r\nProduct             Description           Target Use                      Status            \r\nDSUVIA\u00ae            Sufentanil         Moderate-to-severe      Received FDA approval in      \r\n                   sublingual         acute pain in a         November 2018, commercial     \r\n                   tablet, 30         medically               launch began Q1 2019.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f16%2f0001437749-20-005304.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Badri N. Dasu", "title": "Chief Engineering Officer"}, {"name": "Pamela Pierce Palmer", "title": "Independent Director & Chief Medical Officer"}, {"name": "Raffi Asadorian", "title": "Chief Financial & Accounting Officer"}, {"name": "Vincent J. Angotti", "title": "Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}